Less expensive Ozempic, Wegovy copies restricted after federal court ruling
Less expensive Ozempic, Wegovy copies restricted after federal court ruling
Show Caption
Hide Caption
Ozempic warning: Experts warn of side effects from weight loss drug
Experts are warning of the possible side effects of popular diabetes medications such as Ozempic and Mounjaro when used for weight loss.
The pharmaceutical company that makes the weight-loss drug Wegovy and the diabetes medication Ozempic secured a court victory that limits compounding pharmacies from selling versions of those popular drugs.
A federal judge April 24 rejected a bid by compounding pharmacies to continue selling less expensive copies of semaglutide, Novo Nordisk's blockbuster drug sold under the brands Wegovy and Ozempic.
The court ruling closes a legal window that allowed compounding pharmacies to make and sell large quantities of the lucrative weight-loss drugs. Many consumers turned to these less-expensive compounded versions of the weight-loss and diabetes drugs because they said they could not afford the brand medications.
The Food and Drug Administration allows compounding pharmacies to sell copies of drugs when the medications are in short supply. In February, the FDA declared the semaglutide shortage over and set deadlines for enforcement action against compounding pharmacies and facilities that essentially copied Novo Nordisk's drug.
The FDA said pharmacies or physicians could face enforcement action if they continued to make or dispense compounded semaglutide products beyond April 22. The FDA set a May 22 deadline for facilities that compound, distribute or dispense semaglutide.
The industry trade group Outsourcing Facilities Association sued the FDA in U.S. District Court in Texas and sought a preliminary injunction to delay enforcement while the court case proceeded. But U.S. District Judge Mark Pittman on Thursday denied compounders' bid for a preliminary injunction.
'We are pleased the court has rejected the compounders' attempts to undermine FDA's data-based decision that the shortage of Wegovy and Ozempic is resolved,' Steve Benz, Novo Nordisk's corporate vice president, legal and general counsel, said in a statement.
Outsourcing Facilities Association Chairman Lee H. Rosebush said the organization is "deeply disappointed" the court failed to consider "clear and convincing evidence" that existing supply of semaglutide doesn't meet consumers' demand.
"We look forward to the opportunity to introduce this evidence again through the legal process and in discussions with the FDA," Rosebush said. "We will not stop in our efforts to ensure that patients can get access to this vital medication.'
In December, the FDA declared that Eli Lilly's weight loss and diabetes medication tirzepatide, sold under the brand names Mounjaro and Zepbound, was no longer in short supply. The Outsourcing Facilities Association unsuccessfully sought a preliminary injunction to continue marketing compounded tirzepatide.
March 5, a federal judge rejected the request for a preliminary injunction. That means pharmacies and facilities that sell batches of the medication could face FDA enforcement.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
41 minutes ago
- Yahoo
Safe Group announces FDA 510(k) clearance for SpineUp's Frida solution
Safe Group announces FDA 510(k) clearance for SpineUp's Frida solution Fleurieux-sur-l'Arbresle - France - June 5, 2025 at 6 p.m. Safe Group, a leading player in the field of medical devices for spine surgery, is pleased to announce that Frida, the innovative cervical plate developed by SpineUp, has received 510(k) clearance from the Food and Drug Administration (FDA). This clearance marks a crucial step in SpineUp's expansion into the North American market, and testifies to its ongoing commitment to providing cutting-edge medical solutions. Frida is a new-generation cervical plate offering high adaptability with a multiplicity of plate and screw sizes. Thanks to this technology, healthcare professionals will be able to offer more personalized treatments, tailored to the specific needs of surgeons and their patients. FDA 510(k) clearance is the result of several years of research and development. This certification attests to the safety and efficacy of the Frida solution, which complies with the FDA's strict standards and is due to be marketed by the end of the year. « In view of the merger of Safe's subsidiaries with SpineUp, we are delighted that this authorization has been granted and that SpineUp has taken a major step forward, validating the company's commitment to innovation and improving patient care," says Victor Humberdot, Chairman of Safe Group. 'This new step heralds new business opportunities for SpineUp and its subsidiaries Safe Orthopaedics and Safe Medical, increased synergy and a stronger foothold in the U.S.' comments Philippe Laurito, President of SpineUp Inc. About Safe Group Safe Group is a French medical technology group that brings together Safe Orthopaedics, a pioneer in ready-to-use technologies for spine pathologies, and Safe Medical (formerly LCI Medical), a medical device subcontractor for orthopedic surgeries. The group employs approximately 100 Orthopaedics develops and manufactures kits combining sterile implants and ready-to-use instruments, available at any time to the surgeon. These technologies are part of a minimally invasive approach aimed at reducing the risks of contamination and infection, in the interest of the patient and with a positive impact on hospitalization times and costs. Protected by 15 patent families, SteriSpineTM kits are CE marked and FDA approved. Safe Orthopaedics has subsidiaries in the United Kingdom, Germany, the United more information: Safe Medical produces implantable medical devices and ready-to-use instruments. It has an innovation center and two production sites in France and in Tunisia, offering numerous industrial services: industrialization, machining, finishing and sterile more information: ContactsSAFE GROUP AELYON ADVISORSinvestors@ safe@ Attachment Safe_PR_SpineUp_FDA
Politico
an hour ago
- Politico
RFK Jr. guts ACIP. What happens next?
Presented by Driving the day ACIP FIRINGS ROCK WASHINGTON — HHS Secretary Robert F. Kennedy Jr. abruptly removed 17 vaccine experts from the CDC's Advisory Committee on Immunization Practices on Monday — and Washington is already reeling. 'The committee has been plagued with persistent conflicts of interest and has become little more than a rubber stamp for any vaccine,' Kennedy wrote in an opinion piece published in The Wall Street Journal. He wrote that the decision is meant to restore faith in vaccines. Public health experts and Democrats immediately condemned the action — which POLITICO reported was under consideration in February. 'This is absolutely unprecedented. RFK Jr. has many levers at his disposal to influence vaccine policy in the U.S., each with varying degrees of impact. But this move is a red-alert, level 4 alarm,' said Katelyn Jetelina, an epidemiologist who's consulted for the CDC. The biopharmaceutical industry also raised concerns. 'A wholesale change of this manner will negatively affect the Committee's ability to deliberate and make well-informed recommendations, putting American lives at risk,' Biotechnology Innovation Organization CEO John Crowley said in a statement. 'We agree that transparency is key to restoring trust in immunizations; however, the actions taken today upend a time-tested system that has protected American public health.' The removal of the experts also appears to buck the commitment Kennedy made to Senate Health, Education, Labor and Pensions Chair Bill Cassidy (R-La.) to 'maintain' the committee 'without changes.' But Cassidy told reporters at the U.S. Capitol that he spoke with Kennedy twice Monday and that the assurance he'd won from the now-secretary concerned ACIP's structure rather than membership. 'Of course, now the fear is that the ACIP will be filled up with people who know nothing about vaccines except suspicion,' Cassidy posted on X after the announcement. That fear was echoed by Democrats — who slammed the decision as a dangerous action that puts the health of Americans at risk. 'Secretary Kennedy is firing the 17 medical experts that advise our nation on immunization practices so he can stack the panel with a bunch of anti-vaccine wackos,' House Energy and Commerce ranking member Frank Pallone (D-N.J.) said in a statement. Remember: FDA Commissioner Marty Makary slammed ACIP as a 'kangaroo court' earlier this month on CBS' 'Face the Nation.' What's next: HHS said ACIP will still meet June 25-27, but with new membership. IT'S TUESDAY. WELCOME BACK TO PRESCRIPTION PULSE. Do you know how the decision to fire ACIP members went down? Send your tips to David Lim (dlim@ @davidalim or davidalim.49 on Signal) and Lauren Gardner (lgardner@ @Gardner_LM or gardnerlm.01 on Signal). Eye on the FDA DECISION TIME ON RSV — Two drug products targeting respiratory syncytial virus — a common bug that can cause severe illness in young babies and older adults — are on deck FDA decisions this week. Another antibody: The agency approved Merck's preventive monoclonal antibody Monday — a day ahead of schedule — for infants' first RSV season, injecting more competition into the RSV market. The company has designed the drug, dubbed Enflonsia, to be the same single dose administered to babies of any weight — a departure from Sanofi's Beyfortus, which is made in different dosage amounts depending on a baby or toddler's age and weight. Dr. Octavio Ramilo of St. Jude Children's Research Hospital, who worked as an investigator for Merck's trials for the drug, said its 'dosing convenience' and strong evidence showing reductions in disease and hospitalization make Enflonsia 'a promising new intervention to help protect infants from RSV.' Merck said it expects the CDC's external vaccine panel to make recommendations for the antibody's use at its next meeting in late June. The company statement came out just before HHS Secretary Robert F. Kennedy Jr.'s op-ed on the Advisory Committee on Immunization Practices was published. Another vaccine? Moderna is slated to get a decision on its mRNA vaccine for RSV in high-risk adults under 60 by Thursday. The FDA approved mResvia last year for adults 60 and older, and the company has said the shot met its study goals in the younger population. But Kennedy's suspicion of mRNA technology has prompted the federal government to pull funding from Moderna's bird flu vaccine program and to condition future Covid vaccine approvals for healthy people on more data, making the FDA's decision this week worth watching. Moderna stopped working on a version of the vaccine for children last year after receiving reports of severe lower respiratory tract infections in immunized trial participants. In Congress IN THE HOT SEAT — President Donald Trump's cuts to ideologically disfavored research have left the National Institutes of Health with unspent funds. Director Jay Bhattacharya, under pressure from critics on Capitol Hill and in the research community, is pledging to change that. But Democrats will get a chance to ask Bhattacharya for more details when he testifies before a Senate Appropriations subcommittee this morning. Pharma Moves Dr. Jennifer Peña is joining women's telehealth company Wisp as chief medical officer. She previously worked in similar roles at Oscar Health and Nurx and served as a White House physician under Barack Obama and Donald Trump. Document Drawer The FDA is publicizing a voluntary recall by Church & Dwight Co. of its Zicam nasal swabs and Orajel baby teething swabs due to potential fungi microbial contamination in the cotton swab components. No serious adverse events have been reported to date. The White House Office of Information and Regulatory Affairs is reviewing a 340B rebate guidance from the Health Resources and Services Administration. WHAT WE'RE READING STAT's Helen Branswell examines efforts by philanthropic leaders to maintain a network of labs that conduct surveillance of measles and rubella around the world following cuts by the Trump administration to global aid dollars. A bipartisan bill that tackles tools Medicare Advantage plans use to get higher payments from the federal government could be included in Senate Republicans' megabill, but a key Democrat doesn't want it in the package, POLITICO's Robert King and Meredith Lee Hill report. Nearly 50 food industry groups and companies are being invited by the White House to discuss a recent report on its Make America Healthy Again goals, POLITICO's Grace Yarrow reports.
Yahoo
an hour ago
- Yahoo
GT Medical Technologies Names James Leech Chief Financial and Strategy Officer
Experienced Life Sciences Executive Joins Leadership Team as Company Further Advances Commercialization of GammaTile® TEMPE, Ariz., June 10, 2025 /PRNewswire/ -- GT Medical Technologies, a medical device company with a corporate purpose of improving the lives of patients with brain tumors, today announced that James Leech, a seasoned financial and operational life sciences leader, has joined the company as Chief Financial and Strategy Officer. "We are excited to welcome James as he assumes the Chief Financial and Strategy Officer role at GT Medical Technologies," said Per Langoe, CEO of GT Medical Technologies. "I look forward to collaborating with him to ensure even more doctors and patients have access to GammaTile®. With over 10 years of successful experience leading commercial-stage healthcare-focused companies in an advisory and operational capacity, his expertise on a range of traditional and complex financial and strategic management areas provides us with a substantial opportunity for continued growth and adoption." Mr. Leech will work across the team to accelerate commercial opportunities for GammaTile while spearheading corporate strategy and development, as well as financial and investor management. "I look forward to joining a leadership team that is dedicated to transforming the lives of patients with brain tumors," said Mr. Leech. "GT Medical Technologies is poised for significant growth, and I am thrilled to collaborate with all stakeholders to optimize the company's continued expansion of GammaTile, our FDA-cleared bioresorbable radiotherapy implant for the treatment of brain tumors." Mr. Leech has considerable experience leading businesses from inception through hyper growth phases of their life cycle. He has advised and worked across the life science industry with direct experience in MedTech, healthcare services, and biopharmaceutical sectors across all major therapeutic areas. Previously, Mr. Leech was the Chief Financial and Strategy Officer of Moximed, a commercial-stage orthopedic device company. Prior to Moximed, Mr. Leech was the Chief Business Officer at Palette Life Sciences from the Company's inception through its acquisition by Teleflex, Inc. Mr. Leech started his career in life science investment banking and strategy consulting. He brings significant cross-border experience, having executed transactions and operational initiatives on behalf of and involving companies across the EU and APAC. GammaTile is an innovative form of radiation therapy placed at the time of tumor removal surgery, delivering immediate, targeted radiation to the tumor site when cancer cells are most vulnerable. Unlike conventional approaches, which at their lowest often require a delay between surgery and radiation therapy to allow for wound healing, GammaTile eliminates this treatment gap. By delivering immediate, localized radiation directly at the tumor site, it is designed to maximize the treatment's effectiveness against remaining cancer cells and reduce the risk of regrowth.1 About GT Medical Technologies, Medical Technologies was founded by a dedicated team of brain tumor specialists to address unmet needs in brain tumor treatment. The company is committed to improving the lives of patients with brain tumors through innovative solutions that elevate the standard of care. About GammaTileGammaTile is an FDA-cleared, bioabsorbable collagen implant embedded with radiation seeds, designed for patients with operable brain tumors. By delivering radiation directly from within—placed into the surgical cavity at the time of tumor removal—GammaTile provides immediate, localized treatment. This approach targets remaining cancer cells when they are most vulnerable to help prevent regrowth, while minimizing radiation exposure to healthy brain tissue. Since its full market launch in the United States in March 2020, GammaTile has been adopted by more than 100 leading centers, underscoring its growing acceptance in both academic and community healthcare settings. For more information, visit and follow @GammaTile on Facebook, Instagram, LinkedIn and X. Media ContactDawn FallonNew Dawn Communications LLCDfallon@ References Garcia MA et al. J Neurooncol. 166:203-212 (2024). View original content to download multimedia: SOURCE GT Medical Technologies
